Weaver will explain her personal methodology for validating and correlating qualitative-predictive assays, particularly HER2, an important breast cancer biomarker.
Go here for information about the webinar.
The National Cancer Institute has contracted with PGXL Technologies, sister company of PGXL Labs, to develop new detection methods for circulating tumor cells. The methods will take advantage of PGXL Tech’s single-cell separation technology. Press release here.
Dr. Mark Linder and Dr. Roland Valdes Jr. were honored by University of Louisville at the 2013 Celebration of Faculty Excellence on Sept. 9. Dr. Linder and Dr. Valdes Jr. were recognized for their patent invention, PerMIT.
To read the full press release, please click here.
Greater Louisville, Inc., Louisville’s Metro Chamber of Commerce, honored PGXL Laboratories with the 2013 Inc.credible Awards for Innovation and Technology. The Innovation and Technology category recognizes a company in the Louisville area that best uses technology to enhance its productivity, operations, and revenue opportunities.
“We’re thrilled to receive GLI’s Inc.credible Award for Innovation and Technology. Greater Louisville, Inc. is such an important part of the city and we are honored to be recognized by them,” says Dr. Roland Valdes Jr., President of PGXL.
To view the press release, please click here.
We’re adding Silicon Biosystems’ DEPArrayTM to our already impressive set of capabilities. DEPArray is a technology that allows researchers to sort samples one cell at a time, delivering the cell purity needed for stringent downstream applications like next-gen sequencing and RNA expression profiling.
Making the DEPArray available is a collaboration between PGXL Technologies and Silicon Biosystems. The DEPArray will be available on a fee-for-service basis beginning Summer, 2013.
The press release about the collaboration is here.
The United States Patent and Trade Office has issued patent number 8380539 for PerMIT, PGXL’s decision support software. The application has been working its way through the process since 2006, and we’d like to congratulate the inventors, Dr. Roland Valdes, Jr., and Dr. Mark Linder, on the software’s jump from “patent pending” to “patented.”
The longitudinal, real-time version of PerMIT is in clinical trials. The underlying PerMIT knowledge base and algorithms are being used to prepare the interpretive reports physicians get with every PGXL result.
Thrombosis and Haemostasis has published the study we alluded to earlier. The first release of hard data from ongoing trials of PerMIT, PGXL’s decision support software, shows that patients reached stable and therapeutic response to warfarin (Coumadin) in a shorter time when PerMIT guided dosing.
Read about the clinical trials here.
The study was small but striking. It demonstrated a substantial reduction in the time to stability within the target therapeutic range, an improvement in the percentage of time within the therapeutic interval, and a decrease in the frequency of dose adjustments necessary to maintain patients in warfarin’s safe and effective range – all as a result of guidance provided by PerMIT software.
SureGene LLC has chosen PGXL as laboratory provider for it’s proprietary STA2R genetic panel, which uses pharmacogenetic principles to revolutionize the treatment of schizophrenia. The STA2R agreement marks the first collaboration between SureGene and PGXL. SureGene researchers discovered and patented the SULT4A1-1 genetic signature.
“The STA2R panel turns intuitive treatment into precision treatment,” says Dr. Roland Valdes Jr., Chairman and President of PGXL. “It removes the trial and error from the medication of schizophrenia. It’s a perfect application of personalized medicine entirely aligned with PGXL’s vision.”
PGxL Laboratories independently developed the STA2R panel and will perform the tests for healthcare providers around the United States. Both SureGene and PGxL are promoting the test, PGXL through its own distribution system and SureGene direct to psychiatric healthcare providers.
To read the PGXL press release about the STA2R panel, click here.
For much, much more information, visit the STA2R Panel website.